Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma (Q37349875)

19 August 2017

Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma (English)

1 reference

19 August 2017

Monica Prasad Hayes

1

1 reference

19 August 2017

Wayne Douglas

series ordinal

2

1 reference

19 August 2017

Lora Hedrick Ellenson

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

9 March 2009

1 reference

19 August 2017

1 reference

19 August 2017

113

1 reference

19 August 2017

3

1 reference

19 August 2017

370-373

1 reference

Cancer-specific mutations in PIK3CA are oncogenic in vivo

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

High frequency of mutations of the PIK3CA gene in human cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

The phosphoinositide 3-kinase pathway

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

HER-2/neu amplification and overexpression in endometrial carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Overexpression of HER-2/neu in uterine serous papillary cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745284

Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases

2 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.021

Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.021

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.021

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.021

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19272638

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tubal (serous) carcinoma of the endometrium

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19272638

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2008.12.021

1 reference

19 August 2017

1 reference

19 August 2017

1 reference